NDRA

ENDRA Life Sciences Inc. (NDRA) 10Y Growth Potential Analysis (2026)

Invetso Score: 2.5/10 — Weak · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Revenue Growth Drivers

Score: 2.8 (Weak)

NDRA lacks reported five-year revenue, EPS, and FCF CAGR data, limiting evidence of repeatable compounding versus peers with demonstrated multi-year growth.

Negative TTM ROIC suggests incremental capital has not yet translated into scalable revenue expansion, unlike stronger peers that reinvest at positive returns.

Near-zero reported capex intensity may preserve cash, but it also indicates limited visible reinvestment capacity to fund durable long-term growth.

Market Tailwinds

Score:

No disclosed segmentation or concentration metrics make it difficult to verify durable end-market breadth, whereas peers with diversified demand pools show clearer long-term expansion visibility.

The available metrics do not evidence a structural demand tailwind strong enough to offset NDRA’s weak profitability and absent historical growth record.

Without filing-backed proof of recurring demand acceleration, NDRA appears less positioned for sustained multi-year revenue compounding than better-documented peers.

Scalability Expansion

Score:

Negative ROIC and missing operating margin history indicate limited proof that NDRA can scale revenue without destroying capital efficiency, unlike more scalable peers.

The reported leverage profile is modest, but low debt alone does not create expansion capacity when operating economics remain unproven.

Extremely negative cash conversion cycle data is not enough to demonstrate scalable growth, because it may reflect reporting distortions rather than durable operating leverage.

Constraints Limitations

Score:

The main constraint is the absence of filing-backed evidence for sustained historical growth, which materially weakens confidence in long-term compounding versus peers.

Negative TTM ROIC implies structural inefficiency in converting capital into growth, capping the pace at which NDRA can scale relative to stronger operators.

Sparse disclosed operating and segment data limits visibility into repeatable expansion drivers, making long-term revenue durability harder to establish than for better-disclosed peers.

Overall Score

Score:

NDRA shows limited demonstrated capacity to compound revenue over a decade because historical growth evidence is missing and current capital efficiency remains negative versus peers.

Score Driver: Negative Capital Efficiency

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on ENDRA Life Sciences Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →